Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: Lack of association in cystic fibrosis

Chest

Volumn 123, Issue 5, 2003, Pages 1495-1502

  Smith, Arnold L ^a   Fiel, Stanley B ^b   Mayer Hamblett, Nicole ^c   Ramsey, Bonnie ^c   Burns, Jane L ^c  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Antibiotic administration; Cystic fibrosis; Pseudomonas aeruginosa; Pulmonary exacerbation

Indexed keywords

CEFTAZIDIME; PLACEBO; TOBRAMYCIN;

ACCURACY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SPIROMETRY; SPUTUM CULTURE;

EID: 0037541096     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.5.1495     Document Type: Article

References (21)

1. Govan JRW, Nelson JW. Microbiology of lung infection in cystic fibrosis. Br Med Bull 1992; 48:912-930
2. Smith AL, Doershuk C, Goldmann D, et al. Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134:413-421
3. Regelmann WE, Elliott GR, Warwick WJ, et al. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141:914-921
4. McLaughlin FJ, Matthews WJ Jr, Strieder DJ, et al. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis 1983; 147:559-567
5. Beaudry PH, Marks MI, McDougall D, et al. Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? J Pediatr 1980; 97:144-147
6. Saiman L, Burns JL, Whittier S, et al. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol 1999; 37:2987-2991
7. Thomassen MJ, Demko CA, Boxerbaum B, et al. Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis 1979; 140:873-880
8. Shalit I, Stutman HR, Marks MI, et al. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. Am J Med 1987; 82:189-195
9. Smith AL, Ramsey BW, Hedges DL, et al. Safety of aerosol tobramycin administration for three months to patients with cystic fibrosis. Pediatr Pulmonol 1989; 7:265-271
10. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179:1190-1196
11. Burns JL, Ramsey BW, Smith AL. Clinical manifestations and treatment of pulmonary infections in cystic fibrosis. Infect Dis 1993; 8:53-66
12. Seale TW, Thirkill H, Tarpay M, et al. Serotypes and antibiotic susceptibilities of Pseudomonas aeruginosa isolates from single sputa of cystic fibrosis patients. J Clin Microbiol 1979; 9:72-78
13. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340:23-30
14. Davey R, Peckham D, Etherington C, et al. Antibiotic resistance and clinical outcome following intravenous antibiotics therapy for respiratory exacerbation in cystic fibrosis. Paper presented at: the 23rd European Cystic Fibrosis Conference, Stockholm, Sweden, June 2000
15. Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127:725-734
16. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 9th informational supplement; approved standard. Wayne, PA: National Committee for Clinical Laboratory Standards, 1999
17. Buggs CS, Bronstein B, Hirshfeld JW, et al. The in vitro action of streptomycin on bacteria. JAMA 1946; 130:64-67
18. Finland M, Murray R, Harris HW, et al. Development of streptomycin resistance during treatment. JAMA 1946; 132:16-21
19. Murray R, Kilham L, Wilcox C, et al. Development of streptomycin resistance of gram-negative bacilli in vitro and during treatment. Proc Soc Exp Biol Med 1946; 63:470-474
20. Hall WH, Gerding DN, Schierl EA. Penetration of tobramycin into infected extravascular fluids and its therapeutic effectiveness. J Infect Dis 1977; 135:957-961
21. Jackson GG, Riff LJ. Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis 1971; 124(suppl):185-190